Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|June 11, 2014

Cellectis Enters Agreement With CELLforCURE

Cellectis enters an agreement with CELLforCURE for cGMP clinical manufacturing of allogeneic T-cells.

, a company focused on the development of adoptive immunotherapies based on engineered allogeneic Universal Chimeric Antigen Receptor T-cells (UCART) and CELLforCURE, a subsidiary of the biopharmaceutical group LFB, have entered into an agreement in which CELLforCURE will be responsible for the cGMP manufacturing of clinical batches of Cellectis’ allogeneic CART cells. CELLforCURE operates a commercial industrial facility for the production of new therapeutic cell therapies in Les Ulis, France.

The candidates from the UCART product family are allogeneic cell therapy products based on the CAR (Chimeric Antigen Receptor) technology combined with genome engineering. According to the company, engineered allogeneic T-lymphocytes bearing a CAR directed at a tumor antigen are a new potential treatment for the various forms of leukemias, lymphomas, and solid tumors. UCARTs are “off-the-shelf” allogeneic products, which means that UCART production can be standardized, with consistent pharmaceutical release criteria, over time and from batch to batch. The favorable cost of such industrially manufactured treatments may help make them available to a broad patient population and avoid risks associated with the processing and the timing required for an autologous CART process.

Source:


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.